H-1B and green card employer
Novartis Pharmaceuticals Corporation
East Hanover, NJ NAICS 541713
Novartis Pharmaceuticals's new-hire H-1B offers average 1.9 lottery entries, against 2.1 for all employers.
103certified H-1B LCAs, Jul 2025 to Jun 2026
$144,373median offer · middle half $113k to $170k
11%75 vs. 84 LCAs, Oct 2025 to Jun 2026 vs. a year earlier
18certified green card (PERM) cases, FY2026 to Jun 2026
Source U.S. Dept. of Labor, OFLC disclosure files Covers decisions Jul 2025 to Jun 2026 Release FY2026 Q3, published Aug 7, 2026 Wage levels OFLC 2026-27
Lottery entries at Novartis Pharmaceuticals's offers
41 new-employment LCAs · OFLC 2026-27Of every 100 new-employment filings at Novartis Pharmaceuticals:
46 get one entry
22 get two entries
32 get three entries
0 get four entries
Compared with all employers
1 entry · Level I2 · Level II3 · Level III4 · Level IVunder Level I, still 1 entry
How this is calculated
New-employment H-1B LCAs only, the filings behind most cap petitions; extensions, transfers and amendments do not go through the lottery, and cap-exempt universities and nonprofit research organizations are left out. Each offered salary (low end of the range) is compared with the OFLC Level I to IV wages for its occupation and worksite area, wage year 2026-27; a filing with several worksites counts at its lowest level, as the rule requires. Numbers on the right are LCAs. Full methodology.
On the 2025-26 table, used for the March 2026 registration, the same offers average 2.6 entries (29% at Level IV).
Level stated vs level reached
all certified LCAs vs new-employment offersThe level an employer writes on the LCA is the prevailing-wage floor it chose for the job. The salary it offers can sit higher. The lottery counts the salary.
1 entry · Level I2 · Level II3 · Level III4 · Level IVunder Level I, still 1 entry
How this is calculated
New-employment H-1B LCAs only, the filings behind most cap petitions; extensions, transfers and amendments do not go through the lottery, and cap-exempt universities and nonprofit research organizations are left out. Each offered salary (low end of the range) is compared with the OFLC Level I to IV wages for its occupation and worksite area, wage year 2026-27; a filing with several worksites counts at its lowest level, as the rule requires. Numbers on the right are LCAs. Full methodology.
What Novartis Pharmaceuticals offers
103 certified LCAs, Jul 2025 to Jun 2026$50k$100k$150k$200k$250k$300k
Level IIIIIIIVunder Level I = 1 LCA = 1 LCA
$10,000 bands, coloured by the level each salary reaches for its own job and area.
By fiscal year
October to September · hatched: FY2026 to Jun 2026Certified H-1B LCAs
75 FY2026 to Jun 2026
Median offer
$144,373 FY2026
Certified green card cases
18 FY2026 to Jun 2026
Jobs and worksites
Jul 2025 to Jun 2026Top jobs
| Job | Certified LCAs | Median salary |
|---|---|---|
| Data Scientists | 33 | $169,541 |
| Statisticians | 21 | $112,965 |
| Medical and Health Services Managers | 9 | $191,422 |
| Computer Occupations, All Other | 6 | $126,818 |
| Financial Specialists, All Other | 5 | $112,778 |
| Marketing Managers | 4 | $199,410 |
| Computer and Information Systems Managers | 4 | $223,642 |
| Computer and Information Research Scientists | 3 | $185,723 |
Top worksite cities
| City | Certified LCAs | Median salary |
|---|---|---|
| East Hanover, NJ | 92 | $156,863 |
| Cambridge, MA | 6 | $125,154 |
| Durham, NC | 3 | $112,757 |
Green card (PERM) labor certifications
by fiscal year of decision| Fiscal year | Certified | Denied | Median offer |
|---|---|---|---|
| FY2023 | 14 | 0 | $137,811 |
| FY2024 | 16 | 0 | $150,529 |
| FY2025 | 22 | 0 | $175,058 |
| FY2026 to Jun 2026 | 18 | 0 | $162,921 |
Review takes about a year, so a pause in filing shows up a year later. Medians only for years with 3 or more certifications.
Recent certified LCAs
latest 25 · salary is the low end of the offered range| Job title | Salary | Entries |
|---|---|---|
| Director, Forecasting - RENAL PNH | $109,491 | |
| Director, Product Strategy Lead LCM - Immunology | $169,541 | |
| Business Planning and Analysis Manager | $112,778 | |
| Finance Manager | $112,778 | |
| Associate Director, RA Transaction Records | $169,541 | |
| Associate Director, NPS Service Strategy & Standards | $183,186 | |
| AD, Field Ops Excellence | $169,541 | |
| Director, Forecasting-CV | $169,541 | |
| Associate Director, Healthcare Provider Marketing | $199,410 | |
| Associate Director, Statistical Programming | $145,454 | |
| Senior Principal Clinical Data Scientist | $139,506 | |
| Associate Director, AI Technology Lead | $185,723 | |
| Senior Principal Biostatistician | $112,965 | |
| Associate Director, Lead Consultant | $191,422 | |
| QC Systems and Services Manager | $130,289 | |
| Associate Director Biostatistics | $175,781 | |
| Associate Director, AI Tech Lead | $185,723 | |
| Director, Emerging Data Products - NS | $169,541 | |
| Senior Principal Biostatistician | $112,965 | |
| Senior Principal Biostatistician | $144,373 | |
| Associate Director, Payer & Pricing Strategy | $169,541 | |
| Associate Director, Patient and Provider Analytics - CRM | $169,541 | |
| Director, Business Excellence - Immunology | $169,541 | |
| Principal Biostatistician | $112,965 | |
| Business Planning and Analysis Manager | $73,195 |